But you can decrease CIDP anxiety with techniques to stay grounded when you’re dreading an appointment or the return of symptoms. The news that you have a life-changing chronic illness can feel ...
Everyday Health on MSN
How to navigate the emotional challenges of living with CIDP
Get tips to manage health anxiety, loneliness, and other mental health challenges that come with chronic inflammatory demyelinating polyneuropathy.
(ENXTBR:ARGX) reported positive topline data from its Phase 3 ADAPT OCULUS trial of VYVGART in ocular myasthenia gravis. The ...
Efgartigimod alfa–hyaluronidase significantly improves ocular symptoms in adults with ocular myasthenia gravis, according to phase 3 trial data.
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...
The Australian swimmer is an ambassador for Mana Sanctuary, a new co-ed retreat in Canggu that’s geared towards men’s health.
Mordor Intelligence has published a new report on immunoglobulin market offering a comprehensive analysis of trends, growth drivers, and future projections.
A month ago, argenx announced that the FDA had accepted its application to expand Vyvgart to those with acetylcholine ...
Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timeline The designation is supported ...
First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics ...
(NASDAQ:ARGX) used its fourth-quarter earnings call to highlight positive Phase 3 data in ocular myasthenia gravis (MG), continued commercial momentum for VYVGART, and its first year of annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results